Eosinophilic Esophagitis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Bristol Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Allakos,

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Eosinophilic Esophagitis pipeline constitutes 18+ key companies continuously working towards developing 20+ Eosinophilic Esophagitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Eosinophilic Esophagitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Eosinophilic Esophagitis Market.

The Eosinophilic Esophagitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Eosinophilic Esophagitis Pipeline Report: https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Eosinophilic Esophagitis treatment therapies with a considerable amount of success over the years. Eosinophilic Esophagitis Key players such as - Serpin Pharma, Landos Biopharma, Aqilion, Calypso Biotech, Pfizer, EsoCap, Revolo Biotherapeutics, Ellodi Pharmaceuticals, AstraZeneca, and others, are developing therapies for the Eosinophilic Esophagitis treatment
• Eosinophilic Esophagitis Emerging therapies such as - SP 16, Omilancor, AQ280, CALY-002, Etrasimod, Mometasone, IRL201104, APT-1011, Benralizumab, and others are expected to have a significant impact on the Eosinophilic Esophagitis market in the coming years.
• In September 2023, Ellodi Pharmaceuticals LP has initiated phase 3 clinical trials for APT-1011. This study comprises a 24-week randomized, double-blind, placebo-controlled induction research of APT-1011 in adults (≥18 years old) diagnosed with eosinophilic esophagitis (EoE). Following this phase, a single-arm, open-label extension will be conducted. The primary aim is to assess the effectiveness and safety of administering APT-1011 at a 3 mg dosage at bedtime (HS) for inducing a response to treatment (both symptomatic and histologic aspects) over the course of 24 weeks. The subsequent open-label extension seeks to further examine the long-term safety among participants who opt to continue receiving open-label treatment with APT-1011.
• In September 2023, Celgene disclosed the initiation of phase 3 clinical trials for CC-93538. This study adopts an open-label, uncontrolled design aimed at assessing the extended safety and tolerance levels associated with CC-93538 treatment. Enrollment will consist of participants previously engaged in either the CC-93538-EE-001 or CC-93538-DDI-001 studies.

Eosinophilic Esophagitis Overview
Eosinophilic esophagitis (EoE) is a chronic disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus. The esophagus is the tube that carries food from the mouth to the stomach.
Get a Free Sample PDF Report to know more about Eosinophilic Esophagitis Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Eosinophilic Esophagitis Drugs Under Different Phases of Clinical Development Include:
• SP 16: Serpin Pharma
• Omilancor: Landos Biopharma
• AQ280: Aqilion
• CALY-002: Calypso Biotech
• Etrasimod: Pfizer
• Mometasone: EsoCap
• IRL201104: Revolo Biotherapeutics
• APT-1011: Ellodi Pharmaceuticals
• Benralizumab: AstraZeneca
Route of Administration
Eosinophilic Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intravenous

Molecule Type
Products have been categorized under various Molecule types, such as
• Peptide
• Protein
• Propylene glycols
• Cell Therapy

Eosinophilic Esophagitis Pipeline Therapeutics Assessment
• Eosinophilic Esophagitis Assessment by Product Type
• Eosinophilic Esophagitis By Stage and Product Type
• Eosinophilic Esophagitis Assessment by Route of Administration
• Eosinophilic Esophagitis By Stage and Route of Administration
• Eosinophilic Esophagitis Assessment by Molecule Type
• Eosinophilic Esophagitis by Stage and Molecule Type

DelveInsight's Eosinophilic Esophagitis Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Eosinophilic Esophagitis product details are provided in the report. Download the Eosinophilic Esophagitis pipeline report to learn more about the emerging Eosinophilic Esophagitis therapies
https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Eosinophilic Esophagitis Therapeutics Market include:
Key companies developing therapies for Eosinophilic Esophagitis are - Bristol Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Kyowa Hakko Kirin, Allakos, Pfizer, Revolo Biotherapeutics, EsoCap AG, NexEos Diagnostics, Inc., Celgene, and others.
Eosinophilic Esophagitis Pipeline Analysis:
The Eosinophilic Esophagitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Eosinophilic Esophagitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eosinophilic Esophagitis Treatment.
• Eosinophilic Esophagitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Eosinophilic Esophagitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eosinophilic Esophagitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Eosinophilic Esophagitis drugs and therapies-
https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Eosinophilic Esophagitis Pipeline Market Drivers
• Increasing awareness programs for Eosinophil-associated disorders
• Introduction of high-priced biologics

Eosinophilic Esophagitis Pipeline Market Barriers
• Increasing awareness programs for Eosinophil-associated disorders
• Introduction of high-priced biologics.

Scope of Eosinophilic Esophagitis Pipeline Drug Insight
• Coverage: Global
• Key Eosinophilic Esophagitis Companies: Serpin Pharma, Landos Biopharma, Aqilion, Calypso Biotech, Pfizer, EsoCap, Revolo Biotherapeutics, Ellodi Pharmaceuticals, AstraZeneca, and others
• Key Eosinophilic Esophagitis Therapies: SP 16, Omilancor, AQ280, CALY-002, Etrasimod, Mometasone, IRL201104, APT-1011, Benralizumab, and others
• Eosinophilic Esophagitis Therapeutic Assessment: Eosinophilic Esophagitis current marketed and Eosinophilic Esophagitis emerging therapies
• Eosinophilic Esophagitis Market Dynamics: Eosinophilic Esophagitis market drivers and Eosinophilic Esophagitis market barriers

Request for Sample PDF Report for Eosinophilic Esophagitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Eosinophilic Esophagitis Report Introduction
2 Eosinophilic Esophagitis Executive Summary
3 Eosinophilic Esophagitis Overview
4 Eosinophilic Esophagitis- Analytical Perspective In-depth Commercial Assessment
5 Eosinophilic Esophagitis Pipeline Therapeutics
6 Eosinophilic Esophagitis Late Stage Products (Phase II/III)
7 Eosinophilic Esophagitis Mid Stage Products (Phase II)
8 Eosinophilic Esophagitis Early Stage Products (Phase I)
9 Eosinophilic Esophagitis Preclinical Stage Products
10 Eosinophilic Esophagitis Therapeutics Assessment
11 Eosinophilic Esophagitis Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Eosinophilic Esophagitis Key Companies
14 Eosinophilic Esophagitis Key Products
15 Eosinophilic Esophagitis Unmet Needs
16 Eosinophilic Esophagitis Market Drivers and Barriers
17 Eosinophilic Esophagitis Future Perspectives and Conclusion
18 Eosinophilic Esophagitis Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Eosinophilic Esophagitis drugs and therapies-

Related Reports:

Eosinophilic Esophagitis Market https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Eosinophilic Esophagitis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Eosinophilic Esophagitis Epidemiology https://www.delveinsight.com/report-store/eosinophilic-esophagitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Eosinophilic Esophagitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.